Avid Launches Unprecedented Vote of the ACA to Empower Customer Community to Shape Collective Future
Dec 06, 2016 13:01 pm UTC| Business
BURLINGTON, Mass., Dec. 06, 2016 -- Avid® (Nasdaq:AVID), along with leaders of the Avid Customer Association (ACA), today announced the launch of the inaugural ACA Vote, giving current and new ACA members the unique and...
Hawaii Leads the Nation in Gallup-Healthways Well-Being Rankings for Older Americans
Dec 06, 2016 13:01 pm UTC| Business
WASHINGTON and NASHVILLE, Tenn., Dec. 06, 2016 -- Older Americans living in Hawaii, Arizona and New Hampshire have the highest levels of well-being, according to the Gallup-Healthways State of American Well-Being: State...
Hawaii Leads the Nation in Gallup-Healthways Well-Being Rankings for Older Americans
Dec 06, 2016 13:01 pm UTC| Business
WASHINGTON and NASHVILLE, Tenn., Dec. 06, 2016 -- Older Americans living in Hawaii, Arizona and New Hampshire have the highest levels of well-being, according to the Gallup-Healthways State of American Well-Being: State...
Semtech Wins Big at Elektra Awards 2016
Dec 06, 2016 13:01 pm UTC| Business
CAMARILLO, Calif., Dec. 06, 2016 -- Semtech Corporation (Nasdaq:SMTC), a leading supplier of analog and mixed-signal semiconductors, today announced that it won Company of the Year and its LoRa® Wireless RF Technology...
Dec 06, 2016 13:01 pm UTC| Business
Hancock, MD, Dec. 06, 2016 -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, is pleased to...
Dec 06, 2016 13:01 pm UTC| Business
Hancock, MD, Dec. 06, 2016 -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, is pleased to...
Dec 06, 2016 13:01 pm UTC| Business
AUSTIN, Texas, Dec. 06, 2016 -- XBiotech Inc. (NASDAQ:XBIT), developer of True Human™ therapeutic antibodies, today announced that enrollment has been completed in its randomized, placebo-controlled Phase I/II study...